Background: The renin-angiotensin system (RAS) is regarded as one of the most important regulatory systems for cardiovascular homeostasis. In this study, we investigated associations of the five genetic polymorphisms in the RAS and presence of coronary artery disease (CAD) in type 2 diabetes. Methods: Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism analysis. We used the generalised multifactor dimensionality reduction (GMDR) method to identify gene-gene interactions. Results: The D allele in the ACE gene was significantly more frequent in type 2 diabetic patients with CAD (p = 0.04). In multivariate logistic regression analysis, the DD genotype was associated with a significantly increased risk of CAD (p = 0.044). 1675G/A variant in the AT2R gene was found to be associated with CAD in female subjects with type 2 diabetes (p = 0.025). The three other polymorphisms of the RAS do not seem to influence the development of CAD in type 2 diabetes. No significant gene-gene interaction for any combinations of genotypes was found in the GMDR method. Conclusion: The DD variant of the ACE gene polymorphism is associated with increased risk of developing CAD in Chinese patients with type 2 diabetes. A slight impact of AT2R 1675G/A polymorphism on CAD was found only in female diabetic patients.
Introduction
Coronary artery disease (CAD) is a serious complication of type 2 diabetes mellitus (T2DM). In addition to well-recognised risk factors, the renin-angiotensin system (RAS) also has been implicated in the pathogenesis of CAD. The implication of the RAS in the regulation of the cardiovascular system has been well known for many years. It plays a critical role in the stimulation of vascular smooth muscle cell proliferation, intimal fibrosis, inflammatory reactions, prothrombotic processes and plaque calcification. 1 The RAS, which results in the production of vasoactive peptides including angiotensin II (Ang II) and angiotensin (1) (2) (3) (4) (5) (6) (7) [Ang (1) (2) (3) (4) (5) (6) (7) ], are important regulators of vascular function. Many components of the RAS are proteins that may vary in structure, configuration, or quantity because of genetic differences. In recent years, the identification of a number of such variants highlights the interest in this direction. As the prevalence of RAS genetic variants in the general population, it is likely that two or more of them are found in one patient. Several lines of evidence indicate that variations of RAS genes may confer an increased risk for essential hypertension, preeclampsia, stroke, and cardiovascular disease. [2] [3] [4] [5] The most widely studied polymorphism in the RAS is an insertion (I) or deletion (D) of a 287 base pair sequence (rs4646994) in angiotensin-converting enzyme (ACE).
Association between polymorphisms of the renin-angiotensin system and coronary artery disease in Chinese patients with type 2 diabetes
ACE is an ectoenzyme that catalyses the conversion of angiotensin I (Ang I) to the vasoconstrictor Ang II as well as the degradation of the potent vasodilator bradykinin. 6 The expression of vascular tissue ACE is associated with the I/D polymorphism and ACE exerts a potential regulatory effect on Ang II production in the vascular wall. 7 Patients carrying the D allele have a greater risk of developing diabetic nephropathy compared with the I allele. 8 Angiotensin-converting enzyme 2 (ACE2) is the first known human homologue of ACE. In its catalytic domain, this novel enzyme has approximately 42% identical residues with endothelial ACE. In the vasculature, ACE2 converts the vasopressor Ang II into Ang (1-7), a peptide reported to have vasodilatory and cardioprotective properties. ACE2 deficiency is associated with elevated tissue and circulating levels of Ang II and reduced levels of Ang (1-7). 9 Genetic ACE2 ablation led to enhanced vascular inflammation and atherosclerotic plaque formation in apolipoprotein E knockout mice. 10 ACE2 A/G polymorphism (rs2285666), also known as 8790G/A, has been reported to be associated with hypertension in female Chinese patients with metabolic syndrome. 11 The M235T polymorphism of the AGT gene defined by a thymine-cytosine transition at nucleotide 704 in exon 2 resulting in replacement of the methionine by a threonine residue at amino acid position 235 (M235T; rs699). The M235T polymorphism is known to be associated with circulating and tissue AGT. 12 Lanz et al. reported that there is an association of the AGT M235T variant with increased CAD risk. 13 Dysfunction of the vascular endothelium is regarded as an important factor in the pathogenesis of diabetic microand macro-angiopathy. Ang II can also promote atherosclerosis by activation of genes related to coronary calcifications in the vascular smooth muscle cells of coronary arteries. 14 In humans, two subtypes of receptors serve as binding sites for Ang II: angiotensin II type 1 receptor (AT1R) and angiotensin II type 2 receptor (AT2R). Given the broad spectrum of actions of Ang II as an endocrine, autocrine, and intracrine transmitter with AT1R as its primary target in cardiovascular disease, AT1R has been extensively studied. Several AT1R polymorphisms have been found, the most well-studied AT1R single-nucleotide polymorphism (SNP) is A1166C variant (also termed rs5186) at the 3′ untranslated region (3′ UTR). Although this SNP does not lie within a coding region or splice site, it has been hypothesised that it may affect mRNA stability. The A1166C polymorphism of the AT1R gene has been implicated in myocardial infarction, increased aortic stiffness, and hypertension. 15 In isolated human arteries, A1166C polymorphism is associated with an increased response to Ang II. 16 Recently, RAS activation has been implicated in the development of vascular damage in inflammatory conditions. Sakuta et al. have found that the expression of ACE and AT1R are increased in the aortas of adjuvant-induced arthritis rats contributing to increasing vascular oxidative stress and endothelial dysfunction. 17 On the other hand, Ang II stimulation of AT2R receptor antagonises AT1R receptor induced effects. The AT2R is located on the X-chromosome and consists of three exons and two introns, with the entire open reading frame of the gene situated in the third exon. 18 The association of AT2R 1675 G/A with myocardial structure and cardiac disease also has been investigated in several studies. [19] [20] Treatment with both ACE inhibitors 21 and AT1R antagonists 22 may reduce the risks from cardiovascular diseases, further implicating a critical role of the RAS in the pathogenesis of vascular disease.
In the present study, we investigated whether the ACE I/D, AGT M235T, AT1R A1166C, AT2R G1675A, and ACE2 G8790A gene polymorphisms are associated with susceptibility to CAD in Chinese patients with type 2 diabetes.
Subjects and methods

Study population
This study was approved by the Ethics Committee of our hospital. A total of 538 patients with type 2 diabetes were included. All patients enrolled in this study were Chinese and given written, informed consent. Physical examination and laboratory tests were performed in order to evaluate diabetic chronic complications and cardiovascular risk factors. For each subject, historical, clinical, and biochemical data were recorded. Blood pressure was recorded by an electronic device on the right arm in the sitting position after several minutes rest. Arterial hypertension was defined when clearly documented (≥ 140/90 mmHg) or the use of antihypertensive medication. Diabetes mellitus was defined according to the 1999 World Health Organization criteria. Coronary artery disease was documented by angiographic evidence of 75% stenosis of at least one major coronary artery, or a history of prior angioplasty or coronary artery bypass surgery, or myocardial infarction by history validated by electrocardiographic changes. Venous blood samples were obtained after a recommended 12-h fast using standard laboratory techniques for the plasma concentration of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides, and HbA1c, urea nitrogen and creatinine.
Determination of genotypes
A 3 mL venous blood sample was drawn into an EDTA sample tube. Genomic DNA was extracted from wholeblood samples using the TIANamp Blood DNA kit (Tiangen Biotech, Beijing, China), according to the manufacturer's instructions. Five polymorphisms in the RAS system were examined in each diabetic patient with or without CAD.
Genotyping of the ACE gene I/D polymorphism was performed as described previously. 23 Because of the preferential amplification of the D allele compared with the larger I allele, ID heterozygotes can be confused with DD homozygotes. Therefore, we confirmed each DD genotype by using an insertion-specific primer, following a previously described method. 24 For AT2R G1675A genotyping, intron 1 of AT2R was amplified using primers described by Akbar et al. 25 A 310-bp PCR product was cut with Hpy188III for AT2R G1675A polymorphism. The other SNPs were identified following previously established PCR-RFLP conditions: AGT M235T, 26 AT1R A1166C, 27 and ACE2 G8790A. 28 In the absence of the M235T variant (MM genotype), PCR amplification yielded a 165-bp product that was resistant to cleavage by Tth 111I. For the analysis of the AT1R A1166C polymorphism, a 350 bp PCR product was digested with DdeI enzyme. To analyse the ACE2 G8790A polymorphism, the PCR products were digested for 4 h at 37°C with AluI enzyme, electrophoresed on a 2% agarose gel, and stained with ethidium bromide. In order to validate the method used in this study, direct sequencing was also performed by Invitrogen Biotechnology Company (Shanghai, China) using the randomly selected samples. The genotyping details of all polymorphisms, including locations, primers, restriction enzymes, and assay conditions, are listed in Table 1 .
Statistical analysis
Hardy-Weinberg equilibrium (H-W equilibrium) was tested using the χ 2 test. Power calculation using the pwr. chisq.test function of PWR package in R(2.13.1) showed that a sample size of 538 patients provides 88.6% power at the significance level of 0.05 and effect size of 0.15. Data are presented as mean ± SD or median (interquartile range). Normal distribution of continuous variable was evaluated with the Kolmogorov-Smirnov test. To assess differences in normal variables the Indepent samples T test was utilised. Differences in non-normal variables were assessed by the Mann-Whitney U test. Allele frequencies were determined by gene counting. The Pearson χ 2 test was exploited for frequency comparison. Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs). Because of the presence of ACE2 and AT2R in the X chromosome, data for each sex were analysed separately. The SPSS 13.0 program was used for the analysis. Differences were considered statistically significant at value of p < 0.05. Multivariate logistic regression analysis was performed to adjust for other established risk factors of CAD. The II genotype was served as the reference group for ACE I/D analysis, and AA genotype was taken as the reference group for AT1R A1166C analysis. For the AT2R gene, the GG genotype was used as reference and compared with the AG and AA genotypes. For the AGT gene, the MM genotype was used as reference and compared with the MT and TT genotypes. For the ACE2 gene, the GG genotype was used as reference and compared with the AG and AA genotypes. We used the generalised multifactor dimensionality reduction (GMDR) software (http://www.ssg.uab.edu/ gmdr/) to identify gene-gene interactions, a MDR-derived data mining technique discussed in detail elsewhere. 29 In this study, we used 10-fold cross-validation and 1000-fold permutation testing.
Results
Among the 538 patients with type 2 diabetes mellitus, the coronary artery disease group included 220 patients (41%) and the non-coronary artery disease group included 318 patients (59%). The studied groups were compared with respect to clinical findings and biochemical parameters. The baseline characteristics of study participants are summarised in Table 2 . The patients without CAD had significantly higher fasting plasma glucose values (p < 0.05) than those with CAD. Triglyceride (TG) and creatinine (CREA) increased significantly in patients with CAD compared to those without CAD (p < 0.05). The mean age was 65.0 years (± 9.8) for T2DM+CAD group patients and 56.7 years (± 13.8) for T2DM-CAD group patients. This indicates that the incidence of CAD increases with age, especially in the elderly. T2DM+CAD group patients differed from T2DM-CAD group patients for age, fasting plasma glucose, serum HDL cholesterol, total cholesterol and triglyceride levels, HbA 1c , serum creatinine and urea nitrogen.
Because ACE2 and AT2R are on the X chromosome, the H-W equilibrium was only calculated for the female subjects in the T2DM+CAD group and T2DM-CAD group. For the other polymorphisms determined, there was no significant deviation from H-W equilibrium except for the ACE I/D polymorphisms in the T2DM-CAD group, due to an excess of heterozygotes ID.
Polymorphism of the ACE gene was characterised by three genotypes: two deletion alleles (genotype DD), two insertion alleles (genotype II), and heterozygous alleles (genotype ID). The ACE allele frequencies in the T2DM+CAD subjects were 40.9% for the D allele and 59.1% for the I allele. The frequencies in the T2DM-CAD group were 34.7% for the D allele and 65.3% for the I allele (Table 3 ). In multivariate logistic regression analysis (with genotype II as reference), the DD genotype was associated with a significantly increased risk of CAD (OR = 2.05; 95% CI = 1.02-4.12; p = 0.044), but the ID genotype did not show a significant association (p = 0.896) ( Table 4 ). Stratification analyses showed that AT2R G1675A polymorphism was association with CAD risk in female (OR = 1.54; 95% CI = 1.06-2.24; p = 0.025), but not in the male population (Table 3 ). With genotype GG as reference, the AT2R AG genotype was associated with a significantly increased risk of CAD (OR = 0.51; 95% CI = 0.28-0.91; p = 0.023). The same trend was found with AT2R AA genotype (with genotype GG as reference), but not to a statistically significant degree (p = 0.059) ( Table 4 ). In the analysis of the AT1R gene A1166C polymorphism, two cases of the CC genotype were found. In contrast, the AGT M235T, ATR1 A1166C, and ACE2 G8790A gene polymorphisms were not associated with susceptibility to CAD in Chinese type 2 diabetes. Table 5 presents the results of cross-validation consistency (CVC) and testing accuracy obtained from GMDR analysis of the data. None of the models selected by GMDR were statistically significant. According to the GMDR analysis, the most significant combination was the two-locus model, AT2R-G1675A, ACE2-G8790A, which had the maximum cross-validation consistency of 10, yielded a smaller p but was also non-significant (p = 0.061).
Discussion
As CAD is a complex genetic trait, in most cases, involves a number of genes and environmental factors interacting to determine whether or not the disease will develop. Association investigations based on the comparison of allele distribution and genotype in cases and controls are considered a useful method in studying the role of candidate genes in the development of multifactorial and multigenic diseases. Increased activation of the RAS also has been linked to a higher risk of CAD and its complications. In this study we analysed the contribution of genetic variability of five polymorphisms of the RAS to the predisposition for CAD in a group of patients with type 2 diabetes. Logistic regression analysis was used to assess the association of polymorphisms studied with CAD. Odds ratios adjusted for several confounders were calculated. The DD genotype (vs. the II genotype) independently increased the risk of CAD in diabetes 2.1-fold, while the ID genotype did not alter the risk significantly. Therefore, our results suggest that the DD genotype of ACE is an independent risk factor for the development of CAD in type 2 diabetes. The slight differences in the AT2R 1675G/A polymorphism was found only in female patients between the T2DM+CAD group and the T2DM-CAD group. In contrast, the AGT M235T, AT1R A1166C, and ACE2 G8790A gene polymorphisms were not associated with susceptibility to CAD in Chinese type 2 diabetic patients.
To date, quite a number of genes have been examined, which are usually selected based on information regarding 
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Data are presented as mean ± SD or median (interquartile range). SBP: systolic blood pressure, DBP: diastolic blood pressure, FPG: fasting plasma glucose, TC: total cholesterol, TG: triglyceride, HDL-c: high-density lipoprotein cholesterol, LDL-c: low-density lipoprotein cholesterol, BUN: blood urea nitrogen, CREA: creatinine, HbA their function in the RAS signalling pathway. ACE is a key enzyme in the renin-angiotensin system. Most evidence appears to show that the D allele is a risk factor for development and progression of macro-or microvascular diabetic complications. The levels of serum and tissue ACE activity are under genetic control. The DD genotype is associated with higher tissue and plasma ACE levels, whereas the II genotype is associated with lower levels and the ID genotype with middle levels. The reason for the higher ACE levels in the D allele has assumed that the I allele has a sequence similar to a silencer sequence. 30 The association between ACE I/D polymorphism and CAD has been rather controversial. The D allele of the ACE gene has been shown to be an independent risk factor for coronary heart disease in nondiabetic subjects 31 as well as noninsulin-dependent diabetes mellitus (NIDDM) patients. 32 A previously meta-analysis of 15 studies (data from 3394 patients with myocardial infarction and 5479 controls) found the positive effect of an I/D polymorphic variant with myocardial infarction. 33 Similar to our findings, relationship between the D allele of the ACE gene and CAD in diabetes mellitus was demonstrated by Ruiz et al. 32 in 1994. In contrast with all these results, Fujimura et al. 34 concluded that the ACE I/D polymorphism is not an important determinant of CAD. Several reasons may account for the positive association in our study compared with some previous data concerning the negative association of ACE gene polymorphism with CAD. For example, study design, number of studied subjects, ethnic or environmental heterogeneity, and type of diabetes may all contribute to the lack of consistency among different studies. The AT1R receptor A1166C and AGT M235T polymorphisms are also attractive targets when looking for genetic aspect of CAD. Results about the association between the two above-mentioned polymorphisms and CAD have been inconsistent. In a study of Japanese patients with coronary heart disease, the C allele of the AT1R was involved in the development of the coronary artery stenosis. 35 In a recent study investigating the association of RAS gene polymorphisms with CAD in diabetic patients, positive association of AT1R 1166 C and AGT 235T were found, suggesting that RAS activation may play a role in CAD development in subjects with type 2 diabetes. 36 Conversely, Abboud et al. 37 showed that the AT1R allele was not involved in the development of CAD, A1166C genotype frequencies were not significantly different between patients and controls. In contrast to these studies, our results show that the two polymorphisms of the RAS tested in the present study, AGT M235T and AT1R A1166C, do not seem to influence the development of CAD. Ethnic as well as geographical localities differences might be responsible for the observed controversies.
The association between ACE2 G8790A polymorphism and the combination of diabetes and CAD has not been sufficiently studied yet. According to our results, ACE2 G8790A allele is not associated with CAD as an independent risk factor was observed. Another study in a Chinese population revealed that male carriers of the G allele of ACE2 G8790A had higher interventricular septal enddiastolic thickness (IVSTd) and higher left ventricular mass (LVMI) than A allele carriers in patients with type 2 diabetes; however, no obvious difference was found in the genotyping data between the two groups. 38 There are several limitations in our study. First, we chose only one polymorphism per candidate gene in our study. It was not sufficient to capture most relevant genetic information of the candidate genes just by these several SNPs. Further studies with more haplotype tagging or functional SNPs are required to elucidate the role of multiple genetic factors in the development of CAD in type 2 diabetes. Second, the number of subjects in the current study was not sufficient enough after stratification by gender; our results need to be replicated in further studies with larger samples. Third, the present results only provide evidence of the association between RAS gene variations and CAD at the gene level and do not demonstrate the direct mechanism by which RAS causes CAD in type 2 diabetes.
In conclusion, ACE DD polymorphism was found to be independently associated with the presence of CAD after adjustment for other well-known CAD risk factors in type 2 diabetes. The slight differences in the AT2R 1675G/A polymorphism was found only in female patients between the two groups. Diabetic patients with the DD genotype seem to be more prone to CAD based on these results. These results may broaden the knowledge of genetic variants and disease-association studies. This study was performed in Chinese patients, and its applicability to other ethnic group is uncertain and warrants further study.
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